Grant of Award

Oxford Biomedica PLC

02 October 2026

 

OXB

Grant of Award

Oxford, UK – 02 October 2026: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, announces that on 30 September 2026, nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Company’s 2024 Long Term Incentive Plan ("LTIP") as follows:

Type	Name of individual	Title	Number of share options granted
LTIP - Grant in respect of 2026	Eric Schmidhaeuser	Chief Operating Officer	94,156

LTIP - Grant in respect of 2026: The 2026 LTIP metrics are 60% revenue, 40% Operating EBITDA margin, with target ranges in each case assessed on a constant currency basis which is set out in the Company’s Directors’ Remuneration Report for 2025.

1.	Details of the Issuer or emission allowance market participant
a)	Full name of the entity	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
2.	Reason for the notification
a)	Position/status	Chief Operating Officer
b)	Initial notification / amendment	Initial Notification
3.	Details of the person discharging managerial responsibilities / person closely associated
a)	Is this a PDMR or PCA Submission	Submission for PDMR
b)	Name of natural person	Eric Schmidhaeuser
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Date of the transaction	2026-09-30
b)	Description of instrument	Share
c)	Identification code	ISIN: GB00BDFBVT43
d)	Place of the transaction	Outside the trading venue
e)	Currency	GBP – British Pound
f)	Nature of the transaction	Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards.
g)	Price(s) and volumes(s)	Award Price Volume LTIP grant in respect of 2026 Nil 94,156
h)	Aggregated information
	-           Aggregated volume	LTIP awards granted over 94,156 shares in total
	-           Price	Nil

-Ends-

Enquiries: 

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: [phone] / E: [e-mail]

ICR Healthcare:

T: [phone] / E: [e-mail]

Mary-Jane Elliott / Sarah Elton-Farr / Philip Marriage

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

 

END